Candidiasis therapeutics market seen reaching $4.03 billion by 2030

The Business Research Company says the candidiasis therapeutics market will grow from $3.29 billion in 2025 to $3.4 billion in 2026, then to $4.03 billion by 2030. The report points to rising infection rates, more clinical research and broader antifungal treatment options as the main growth drivers.

Why it matters: - Candidiasis is a common fungal infection, and demand for treatment is rising alongside more immunocompromised patients and more hospital-acquired fungal infections. - The market’s growth signals continued spending on antifungal drugs, diagnostics and treatment access across hospitals and outpatient settings. - Faster development of new antifungal options could help address resistance and improve outcomes for patients with oral, genital and systemic infections.

What happened: - The Business Research Company released a candidiasis therapeutics market report on Nov. 6, 2026. - The report estimates the market will rise from $3.29 billion in 2025 to $3.4 billion in 2026. - The report projects the market will reach $4.03 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth through the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - The report says the market’s historical growth was driven by more immunocompromised patients, more hospital-acquired fungal infections, broad use of broad-spectrum antibiotics, established antifungal drug classes and expanding infectious disease treatment facilities in hospitals. - The forecast period is supported by more research into new antifungal drug classes, greater awareness of antifungal resistance, wider adoption of outpatient antifungal therapies, special focus on pediatric candidiasis treatments and more investment in infectious disease drug development. - The report says the key growth driver is a rise in research and clinical trials for new treatment options. - Clinical trials are used to test safety and effectiveness before new drugs reach the market. - ClinicalTrials.gov data showed about 437,533 clinical trials registered in 2023, up from 399,499 in 2022 across the United States and 221 countries. - Candidiasis is caused by an overgrowth of Candida species that normally live in the mouth, throat, gastrointestinal tract and genital regions. - Treatment can include topical antifungal medication or oral antifungal drugs, depending on severity and spread. - The report flags several future trends: more targeted antifungal therapies, earlier and more accurate diagnosis, wider use of combination regimens, more oral and systemic antifungal options and better monitoring of resistance patterns. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - The report suggests the market is moving from basic antifungal use toward more tailored care, with resistance monitoring and combination therapy becoming more important. - The strong clinical trial count reflects a broader research environment that could accelerate innovation in fungal disease treatment. - North America’s current lead and Asia-Pacific’s growth outlook point to a market that is already mature in some regions but still expanding quickly elsewhere.

What's next: - More antifungal drug research and clinical development are likely to shape the next phase of the market. - Wider use of outpatient and oral therapies could shift treatment away from hospital-only care. - Continued attention to pediatric treatment and antifungal resistance may influence both product development and prescribing patterns.